Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8669
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMüller, Lukas-
dc.contributor.authorHahn, Felix-
dc.contributor.authorAuer, Timo Alexander-
dc.contributor.authorFehrenbach, Uli-
dc.contributor.authorGebauer, Bernhard-
dc.contributor.authorHaubold, Johannes-
dc.contributor.authorZensen, Sebastian-
dc.contributor.authorKim, Moon-Sung-
dc.contributor.authorEisenblätter, Michel-
dc.contributor.authorDiallo, Thierno D.-
dc.contributor.authorBettinger, Dominik-
dc.contributor.authorSteinle, Verena-
dc.contributor.authorChang, De-Hua-
dc.contributor.authorZopfs, David-
dc.contributor.authorPinto dos Santos, Daniel-
dc.contributor.authorKlöckner, Roman-
dc.date.accessioned2023-02-13T10:24:51Z-
dc.date.available2023-02-13T10:24:51Z-
dc.date.issued2022-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8685-
dc.description.abstractObjectives: Recently, several scoring systems for prognosis prediction based on tumor burden have been promoted for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). This multicenter study aimed to perform the first head-to-head comparison of three scoring systems. Methods: We retrospectively enrolled 849 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. The tumor burden score (TBS), the Six-and-Twelve score (SAT), and the Seven-Eleven criteria (SEC) were calculated based on the maximum lesion size and the number of tumor nodes. All scores were compared in univariate and multivariate regression analyses, adjusted for established risk factors. Results: The median overall survival (OS) times were 33.0, 18.3, and 12.8 months for patients with low, medium, and high TBS, respectively (p<0.001). The median OS times were 30.0, 16.9, and 10.2 months for patients with low, medium, and high SAT, respectively (p<0.001). The median OS times were 27.0, 16.7, and 10.5 for patients with low, medium, and high SEC, respectively (p<0.001). In a multivariate analysis, only the SAT remained an independent prognostic factor. The C-Indexes were 0.54 for the TBS, 0.59 for the SAT, and 0.58 for the SEC. Conclusion: In a direct head-to-head comparison, the SAT was superior to the TBS and SEC in survival stratification and predictive ability. Therefore, the SAT can be considered when estimating the tumor burden. However, all three scores showed only moderate predictive power. Therefore, tumor burden should only be one component among many in treatment decision making.en_GB
dc.description.sponsorshipGefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577de
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleTumor burden in patients with hepatocellular carcinoma undergoing transarterial chemoembolization : head-to-head comparison of current scoring systemsen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-8669-
jgu.type.contenttypeScientific articlede
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleFrontiers in oncologyde
jgu.journal.volume12de
jgu.pages.alternative850454de
jgu.publisher.year2022-
jgu.publisher.nameFrontiers Mediade
jgu.publisher.placeLausannede
jgu.publisher.issn2234-943Xde
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.3389/fonc.2022.850454de
jgu.organisation.rorhttps://ror.org/023b0x485-
jgu.subject.dfgLebenswissenschaftende
Appears in collections:DFG-491381577-G

Files in This Item:
  File Description SizeFormat
Thumbnail
tumor_burden_in_patients_with-20230126114225062.pdf2.93 MBAdobe PDFView/Open